Solventum earnings release, May 5, 2026

Solventum Corp (SOLV) · Form 8-K, Item 2.02 · Filed · SEC filing

Solventum Reports First Quarter 2026 Financial Results

• R eported sales decreased (3.0)%; organic sales increased 2.1%

• Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing range

EAGAN, Minn., May 5, 2026 – Solventum (NYSE: SOLV) today reported financial results for the first quarter ended March 31, 2026.

First Quarter 2026 Highlights

• S ales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basis

• G

AAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increase

• Operating cash flow of $(189) million; free cash flow of $(273) million

“Solventum delivered first quarter results ahead of expectations, reflecting strong execution and underlying commercial momentum,” said Bryan Hanson, chief executive officer of Solventum. “The work we’re doing to transform the company is reinforcing our confidence in the full year and accelerating progress toward our long-range plan.”

First Quarter 2026 Financial Results¹

Represents non-GAAP financial measure; see the “Non-GAAP Financial Measures” section for applicable information.

Discussion of First Quarter Results

All comparisons are to the prior year period unless otherwise noted

• Organic sales growth of +

2.1% in the quarter reflects strong performance across all reportable segments, primarily driven by volume and product mix.

• GAAP and adjusted gross margin both increased by 80 bps due to programmatic savings, portfolio moves, sales leverage and mix, partially offset by tariffs and inflation headwinds.

• Selling, general and administrative expenses increased primarily due to higher costs associated with separation activities and Transform for the Future, partially offset by restructuring benefits.

• GAAP operating income margin decreased driven by separation and restructuring costs while adjusted operating income margin decreased primarily due to tariffs and inflation, partially offset by operational improvements.

• Operating cash flow for the quarter was

$(189) million and free cash flow was

$(273) million, driven by separation activities, transition agreement exit payments and normal seasonality.¹

Other Business and Operational Highlights

• Celebrated the grand opening of a new 250,000 square foot flagship R&D center of excellence in Eagan, Minnesota, featuring modern workspaces, a pilot factory and a dedicated quality lab to fuel a steady pipeline of healthcare innovation.

• Completed a manufacturing expansion in Brookings, South Dakota, adding 200,000 square feet, 16 shipping docks and an 8,000-pallet warehouse to strengthen production capacity and speed innovations from lab to clinicians.

*Data in the schedule above is intentionally rounded to the nearest million and, therefore, may not sum. “NM” reflects results considered not meaningful due to sale of the Purification and Filtration business in September 2025.²

Constant currency represents the change in net sales absent the impact on sales from foreign currency translation.³

Other represents sales impact from acquisitions and divestitures measured separately for the first 12 months post-transaction. Acquisitions include sales from the December 2025 acquisition of Acera. Divestitures primarily represents lost sales from the Company’s Purification and Filtration business that was sold in September 2025.⁴

All Other includes the drinking water business, which was previously reported within Purification and Filtration, and sales related to product supplied to 3M and other supply agreements related to legacy 3M business and assumed by the Company at Spin-Off.

Full-Year 2026 Guidance

Solventum is affirming its full year 2026 guidance:

• Organic sales growth of +2.0% to +3.0%; +3.0% to +4.0% excluding ~100 bps of SKU exit impact

• Adjusted EPS estimated to be toward the high end of existing $6.40 to $6.60 guidance range

• Free cash flow of ~$200M

Organic sales, adjusted diluted EPS and free cash flow amounts included in Solventum’s full-year guidance are non-GAAP financial measures. Solventum does not provide reconciliations of the forward-looking non-GAAP financial measures to the respective GAAP metrics as it is unable to predict with reasonable certainty and without unreasonable effort certain items, such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items.

See the “Non-GAAP Financial Measures” section for explanations of our non-GAAP financial measures.

Earnings Conference Call

Solventum will host a conference call today, May 5, at 4:30 p.m. Eastern Time to discuss its first quarter financial results and fiscal year 2026 outlook. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers, using the conference ID 6342275.²

A replay of the webcast, along with the earnings press release, slides highlighting the results and supplemental financial disclosures, will also be available at the same link on the Investor Relations section of the Company’s website.

Financial statements

Income Statement

Three months ended March 31, — First Quarter 2026 Financial Results (Dollars in millions, except per share amounts)

Three months ended March 31, – 2026Three months ended March 31, – 2025Three months ended March 31, – Year-over-year change
Net sales2,0072,070-3
Selling, general and administrative expenses8277697.5
Research and development expenses189193-2.1
Operating income margin4.0%7.3%(330) bps
Adjusted operating income margin119.5%19.7%(20) bps
Net income13137-90.5
Diluted earnings per share0.070.78-91
Adjusted diluted earnings per share11.481.3410.6
Net cash provided by (used in) operating activities-18929-751.7
Free cash flow1-273-80-241.3

Income Statement

Three months ended March 31, — (Unaudited)

Three months ended March 31, – 2026Three months ended March 31, – 2025
Net sales of product1,5131,597
Net sales of software and rentals493473
Total net sales2,0072,070
Cost of product796835
Cost of software and rentals115121
Gross profit1,0971,114
Selling, general and administrative expenses827769
Research and development expenses189193
Operating income81152
Interest expense, net62104
Other expense (income), net411
Income before income taxes1638
Provision for (benefit from) income taxes3-99
Net income13137
Earnings per share:Basic earnings per share0.070.79
Earnings per share:Diluted earnings per share0.070.78
Weighted-average number of shares outstanding:Basic174.2173.7
Weighted-average number of shares outstanding:Diluted175.5174.8

Income Statement

BUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Three months ended March 31, 2026 – Net salesBUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Three months ended March 31, 2026 – Operating incomeBUSINESS SEGMENT INFORMATION AND DISAGGREGATED NET SALES* – Three months ended March 31, 2026 – Operating margin %Three months ended March 31, 2025 – Net salesThree months ended March 31, 2025 – Operating incomeThree months ended March 31, 2025 – Operating margin %
Advanced Wound Care497448
Infection Prevention and Surgical Solutions737710
MedSurg1,23416113.1%1,15720617.8%
Dental Solutions3548724.5%3287823.9%
Health Information Systems34213038.1%32910933.1%
Total reportable segment net sales and operating income1,9313791,814393
Purification and FiltrationNM1802715.1%
All Other761215.4%761115.2%
Amortization expense-90-81
Corporate and unallocated-219-198
Total Company2,007814.0%2,0701527.3%

Balance Sheet

December 31, — (Unaudited)

March 31, – 2026December 31, – 2025
Current assetsCash and cash equivalents561878
Current assetsAccounts receivable — net of allowances of $87 and $871,0591,034
Current assetsDue from related parties121150
InventoriesFinished goods643636
InventoriesWork in process222201
InventoriesRaw materials and supplies224229
InventoriesTotal inventories1,0891,066
InventoriesOther current assets754731
InventoriesTotal current assets3,5833,859
InventoriesProperty, plant and equipment — net1,5431,326
InventoriesGoodwill5,6265,704
InventoriesIntangible assets — net2,4972,592
InventoriesOther assets848814
InventoriesTotal assets14,09714,294
Current liabilitiesShort-term borrowings and current portion of long-term debt505
Current liabilitiesAccounts payable699687
Current liabilitiesDue to related parties337435
Current liabilitiesUnearned revenue613621
Current liabilitiesOther current liabilities1,1921,393
Current liabilitiesTotal current liabilities3,3463,136
Current liabilitiesLong-term debt4,5755,035
Current liabilitiesPension and postretirement benefits360363
Current liabilitiesDeferred income taxes161164
Current liabilitiesFinance leases207
Current liabilitiesOther liabilities478547
Current liabilitiesTotal liabilities9,1289,245
EquityCommon stock, par value $0.01 per share, 750,000,000 shares authorized22
Shares - December 31, 2025: issued and outstanding: 173,490,864Additional paid-in capital3,8953,876
Shares - December 31, 2025: issued and outstanding: 173,490,864Retained earnings1,8101,797
Shares - December 31, 2025: issued and outstanding: 173,490,864Treasury stock, at cost-67
Shares - December 31, 2025: 0Accumulated other comprehensive income (loss)-670-625
Shares - December 31, 2025: 0Total equity4,9695,049
Shares - December 31, 2025: 0Total liabilities and equity14,09714,294

Cash Flow

Three months ended March 31, — (Unaudited)

Three months ended March 31, – 2026Three months ended March 31, – 2025
Cash flows from operating activitiesNet income13137
Adjustments to reconcile net income to net cash provided by (used in) operating activitiesDepreciation and amortization135129
Adjustments to reconcile net income to net cash provided by (used in) operating activitiesPension and postretirement benefit expense1415
Adjustments to reconcile net income to net cash provided by (used in) operating activitiesStock-based compensation expense5149
Adjustments to reconcile net income to net cash provided by (used in) operating activitiesDeferred income taxes-41-144
Changes in assets and liabilitiesAccounts receivable-346
Changes in assets and liabilitiesDue from related parties285
Changes in assets and liabilitiesInventories-32-32

Cash Flow

Three months ended March 31, (in millions)

Three months ended March 31, – 2026Three months ended March 31, – 2025
Net cash provided by (used in) operating activities-18929
Net cash used in investing activities-77-114
Net cash used in financing activities-50-139
Free cash flow (non-GAAP measure)Net cash provided by (used in) operating activities-18929
Free cash flow (non-GAAP measure)Purchases of property, plant and equipment-84-109
Free cash flow (non-GAAP measure)Free cash flow-273-80
Full release

Forward-Looking Statements

This... (truncated)herently uncertain and outside of Solventum’s control. Forward-looking statements include those containing such words as “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “guidance,” “intends,” “may,” “outlook,” “plans,” “potential,” “predicts,” “projects,” “seeks,” “sees,” “should,” “targets,” “will,” “would” or other words of similar meaning or by using future dates in connection with the discussion of, among other things, statements expressing general views about future operating or financial results, operating or financial performance, trends, events or developments that we expect or anticipate will occur in the future, anticipated cost savings, the launch and acceptance of new products and changes in the global economic environment. It is possible that Solventum’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, including from risks and uncertainties related to, among others: competition and disruption in the healthcare industry; global economic, political and geopolitical conditions; changes in trade and tariff policies; changes in legislation or practices related to reimbursement, regulatory requirements and approvals; the development, manufacturing, marketing and sale of healthcare products; supply chain and operational execution; acquisitions, divestitures and other strategic transactions; Solventum’s separation from 3M and performance as a standalone company, including the tax-free nature of the spin and its ability to execute on its short- and long-range plans and capital allocation strategies; artificial intelligence, information technology and cybersecurity risks; restructuring programs, and other risks and uncertainties described in Solventum’s filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10‑K and Quarterly Report on Form 10‑Q. Solventum’s management believes that these forward-looking statements are reasonable as of the time made. However, caution should be taken not to place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. Solventum undertakes no obligation to update any forward‑looking statements or other information in this press release as a result of new information, future events or otherwise, except as required by applicable law.

Non-GAAP Financial Measures

In addition to reporting financial results in accordance with U.S. GAAP, Solventum also provides non-GAAP measures that we use, and plan to continue using, when monitoring and evaluating operating performance and measuring cash available to invest in our business. The adjusted measures are not in accordance with, nor are they a substitute for, GAAP measures. These non-GAAP financial measures are supplemental measures of our performance and our liquidity that we believe help investors understand our underlying business performance and Solventum uses these measures as an indication of the strength of Solventum and its ability to generate cash.

Solventum calculates forward-looking non-GAAP financial measures, including organic sales growth, adjusted gross margin, adjusted operating income, adjusted operating income margin, adjusted effective tax rate, adjusted diluted earnings per share and free cash flow based on internal forecasts that omit certain amounts that would be included in GAAP financial measures. Solventum does not provide reconciliations of these forward-looking non-GAAP financial measures to the most directly comparable GAAP measures as it is unable to predict with reasonable certainty and without unreasonable effort certain items such as the impact of changes in currency exchange rates, impacts associated with business acquisitions or divestitures, and the timing and magnitude of restructuring activities, among other items. The timing and amounts of these items are uncertain and could have a material impact on Solventum’s results in accordance with GAAP.

The Q1 2026 financial statements and financial information, including reconciliations of non-GAAP financial measures, are available on Solventum’s website: investors.solventum.com.

About Solventum

At Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pioneer game-changing innovations at the intersection of health, material and data science that change patients’ lives for the better — while empowering healthcare professionals to perform at their best. See how at Solventum.com.³

Solventum Investor Contact: investors@solventum.com

Solventum Media Contact: news@solventum.com⁴

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Solventum earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.